[go: up one dir, main page]

WO2010087981A3 - Bicyclic amide derivatives for enhancing glutamatergic synaptic responses - Google Patents

Bicyclic amide derivatives for enhancing glutamatergic synaptic responses Download PDF

Info

Publication number
WO2010087981A3
WO2010087981A3 PCT/US2010/000255 US2010000255W WO2010087981A3 WO 2010087981 A3 WO2010087981 A3 WO 2010087981A3 US 2010000255 W US2010000255 W US 2010000255W WO 2010087981 A3 WO2010087981 A3 WO 2010087981A3
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
treatment
disorders
compounds
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/000255
Other languages
French (fr)
Other versions
WO2010087981A2 (en
Inventor
Rudolf Mueller
Leslie J. Street
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortex Pharmaceuticals Inc
Original Assignee
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2011547981A priority Critical patent/JP2012516845A/en
Priority to AU2010208646A priority patent/AU2010208646A1/en
Priority to BRPI1005316A priority patent/BRPI1005316A2/en
Priority to CA2751285A priority patent/CA2751285A1/en
Priority to EA201101162A priority patent/EA018994B1/en
Priority to SG2011054376A priority patent/SG173168A1/en
Priority to CN2010800154033A priority patent/CN102369201A/en
Priority to MX2011008060A priority patent/MX2011008060A/en
Application filed by Cortex Pharmaceuticals Inc filed Critical Cortex Pharmaceuticals Inc
Priority to EP10736150A priority patent/EP2391621A4/en
Publication of WO2010087981A2 publication Critical patent/WO2010087981A2/en
Publication of WO2010087981A3 publication Critical patent/WO2010087981A3/en
Priority to IL214392A priority patent/IL214392A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as conditions such as stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
PCT/US2010/000255 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses Ceased WO2010087981A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN2010800154033A CN102369201A (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for the treatment of respiratory depression
BRPI1005316A BRPI1005316A2 (en) 2009-02-02 2010-01-29 compound, pharmaceutical composition, methods for treating and using a compound
CA2751285A CA2751285A1 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
EA201101162A EA018994B1 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
SG2011054376A SG173168A1 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
JP2011547981A JP2012516845A (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
AU2010208646A AU2010208646A1 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
MX2011008060A MX2011008060A (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses.
EP10736150A EP2391621A4 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
IL214392A IL214392A0 (en) 2009-02-02 2011-08-01 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20664209P 2009-02-02 2009-02-02
US61/206,642 2009-02-02

Publications (2)

Publication Number Publication Date
WO2010087981A2 WO2010087981A2 (en) 2010-08-05
WO2010087981A3 true WO2010087981A3 (en) 2011-03-24

Family

ID=42396261

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/000255 Ceased WO2010087981A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
PCT/US2010/000254 Ceased WO2010087980A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for the treatment of respiratory depression

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000254 Ceased WO2010087980A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for the treatment of respiratory depression

Country Status (12)

Country Link
EP (1) EP2391621A4 (en)
JP (1) JP2012516845A (en)
KR (1) KR20110115139A (en)
CN (1) CN102369201A (en)
AU (1) AU2010208646A1 (en)
BR (1) BRPI1005316A2 (en)
CA (1) CA2751285A1 (en)
EA (1) EA018994B1 (en)
IL (1) IL214392A0 (en)
MX (1) MX2011008060A (en)
SG (1) SG173168A1 (en)
WO (2) WO2010087981A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035950A1 (en) * 1997-02-13 1998-08-20 Cortex Pharmaceuticals, Inc. Benzofurazan compounds which enhance ampa receptor activity
WO1999021422A1 (en) * 1997-10-27 1999-05-06 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
WO2008143963A1 (en) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0651746T3 (en) * 1992-07-24 2002-07-29 Univ California Drugs that enhance synaptic responses mediated by AMPA receptors
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
BRPI0823262A2 (en) * 2007-08-10 2013-09-24 Cortex Pharma Inc Respiratory depression treatment method and use of a compound in the manufacture of a medicament for the treatment of respiratory depression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035950A1 (en) * 1997-02-13 1998-08-20 Cortex Pharmaceuticals, Inc. Benzofurazan compounds which enhance ampa receptor activity
WO1999021422A1 (en) * 1997-10-27 1999-05-06 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
WO2008143963A1 (en) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
SG173168A1 (en) 2011-08-29
JP2012516845A (en) 2012-07-26
CA2751285A1 (en) 2010-08-05
EP2391621A4 (en) 2012-07-25
EA201101162A1 (en) 2012-01-30
EP2391621A2 (en) 2011-12-07
IL214392A0 (en) 2011-09-27
KR20110115139A (en) 2011-10-20
WO2010087980A3 (en) 2011-02-24
WO2010087981A2 (en) 2010-08-05
EA018994B1 (en) 2013-12-30
AU2010208646A1 (en) 2011-09-01
CN102369201A (en) 2012-03-07
MX2011008060A (en) 2011-09-09
WO2010087980A2 (en) 2010-08-05
BRPI1005316A2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
MX2009012430A (en) Di-substituted amides for enhancing glutamatergic synaptic responses.
WO2009023126A3 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
WO2009038752A3 (en) 3-substituted 1,2,3-triazin-4-one&#39;s and 3-substituted 1,3-pyrimidinone&#39;s for enhancing glutamatergic synaptic responses
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
Weiergräber et al. Voltage-gated calcium channels in the etiopathogenesis and treatment of absence epilepsy
TN2009000277A1 (en) 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses
MX2009004071A (en) Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto.
HUE046494T2 (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
DOP2011000138A (en) NEW COMPOUNDS 578
WO2009109493A3 (en) 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists
WO2008153958A3 (en) Crystalline forms of (r)-1-{2-[4&#39;- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
WO2010087981A3 (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
HUP0900231A2 (en) Compositions for the treatment of allergic disorders and process for producing them
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
EP2552473A4 (en) Methods for treating parkinson&#39;s disease and other disorders of dopaminergic neurons of the brain
WO2003045315A3 (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
WO2007061741A3 (en) Modulators of the h3 receptor useful for the treatment of disorders related thereto
UA93306C2 (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
HK1126385A (en) Method and apparatus of noninvasive, regional brain thermal stimuli for the treatment of neurological disorders
TN2010000565A1 (en) Compounds comprising a cyclobutoxy group
HK1188453A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
TH102412A (en) Biphenylsulfonyl regulators And phenyl-heteroaryylsulfonyl of histamine. H3-receptors are useful for treating disorders associated with that receptor.
ATE452633T1 (en) USE OF AN ANTI-ATHEROTHROMBOTIC SUBSTANCE FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF CEREBRAL VASCULAR DISORDERS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080015403.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/008060

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 214392

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2751285

Country of ref document: CA

Ref document number: 2011547981

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 6059/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010736150

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010208646

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20117019461

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2010208646

Country of ref document: AU

Date of ref document: 20100129

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 594954

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 201101162

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10736150

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI1005316

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110729